Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma
Abstract Our study aimed to analyze the reported cardiovascular AEs (CVAEs) associated with approved bispecific T-cell engagers (BiTEs) for multiple myeloma (MM), providing insights that could guide safer clinical use of BiTEs. Data were obtained from the FDA Adverse Event Reporting System (FAERS) d...
Saved in:
| Main Authors: | Chang Shan, Yanli Zhang, Xinxin Zhang, Lu Li, Yanwei Chen, Ying Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-03391-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma
by: Xiaoling Zhou, et al.
Published: (2025-08-01) -
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01) -
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
by: Andrée-Anne Pelland, et al.
Published: (2025-04-01) -
Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01) -
Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
by: Wenze Li, et al.
Published: (2025-04-01)